Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.

被引：15

作者：

Foss, Francine M.

Querfeld, Christiane

Kim, Youn H.

Pinter-Brown, Lauren C.

William, Basem M.

Porcu, Pierluigi

Pacheco, Theresa

Haverkos, Bradley

DeSimone, Jennifer

Guitart, Joan

Halwani, Ahmad Sami

Eradat, Herbert Aaron

Huen, Auris

Seto, Anita G.

Pestano, Linda A.

Gordon, Gilad Shalag

Escolar, Diana

Rubin, Paul

Marshall, William S.

Williams, Jud

机构：

[1] Yale Canc Ctr, Woodbridge, CT USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Stanford Canc Ctr, Cupertino, CA USA

[4] UCLA, Beverly Hills, CA USA

[5] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Columbus, OH USA

[6] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Jefferson, PA USA

[7] Univ Colorado, Sch Med, Aurora, CO USA

[8] Inova Schar Canc Inst, Fairfax, VA USA

[9] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA

[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[11] Univ Calif Los Angeles, Los Angeles, CA USA

[12] Univ Texas MD Anderson Canc Ctr, Div Internal Med, Dept Dermatol, Houston, TX 77030 USA

[13] Miragen Therapeut Inc, Boulder, CO USA

[14] ORRA Grp LLC, Boulder, CO USA

[15] MiRagen Therapeut, Boulder, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.2511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2511

引用

页数：1